Jefferies Maintains Apellis Pharmaceuticals(APLS.US) With Buy Rating, Maintains Target Price $80

Jefferies analyst Akash Tewari maintains $Apellis Pharmaceuticals(APLS.US)$ with a buy rating, and maintains the target price at $80.According to TipRanks data, the analyst has a success rate of 59.5%

Moomoo NewsJul 19 08:31 ET · Ratings

Jefferies Keeps Their Buy Rating on Apellis Pharmaceuticals (APLS)

TipRanksJul 19 08:06 ET

Apellis Pharmaceuticals to Host Conference Call on August 1, 2024, to Discuss Second Quarter 2024 Financial Results

WALTHAM, Mass., July 18, 2024 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will host a conference call and webcast to discuss its second

Apellis PharmaceuticalsJul 18 00:00 ET

Peeling Back The Layers: Exploring Apellis Pharmaceuticals Through Analyst Insights

Across the recent three months, 12 analysts have shared their insights on Apellis Pharmaceuticals (NASDAQ:APLS), expressing a variety of opinions spanning from bullish to bearish.The table below

BenzingaJul 17 13:01 ET

Express News | Goldman Sachs Maintains Buy on Apellis Pharmaceuticals, Lowers Price Target to $77

BenzingaJul 17 11:57 ET

Apellis Pharmaceuticals (NASDAQ:APLS) Shareholders Are up 9.8% This Past Week, but Still in the Red Over the Last Year

Investing in stocks comes with the risk that the share price will fall. And unfortunately for Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) shareholders, the stock is a lot lower today than it was a

Simply Wall StJul 12 06:23 ET